The Federal Trade Commission (FTC), in collaboration with the Department of Justice (DOJ), the Department of Health and Human Services, and the Department of Commerce, will host a series of listening sessions aimed at reducing prescription drug prices through enhanced competition. This initiative is part of President Trump's Executive Order No. 14273, titled "Lowering Drug Prices by Once Again Putting Americans First."
The sessions are designed to address pharmaceutical affordability by increasing access to generic and biosimilar drugs and fostering competitive practices within drug formularies and benefits. According to FTC Chairman Andrew Ferguson, these discussions will feature insights from practitioners and scholars on anticompetitive behaviors and strategies for eliminating regulatory barriers.
Assistant Attorney General Gail Slater from the DOJ Antitrust Division emphasized that the findings from these sessions will contribute to a joint report focused on combating anticompetitive practices in pharmaceutical markets, as required by the executive order.
The listening sessions will be available via live stream, with recordings and transcripts accessible afterward. The schedule is as follows:
- Monday, June 30 at 2 pm ET: Anticompetitive Conduct by Pharmaceutical Companies Impeding Generic or Biosimilar Competition.
- Thursday, July 24 at 2 pm ET: Formulary and Benefit Practices and Regulatory Abuse Impacting Drug Competition.
- Monday, August 4 at 2 pm ET: Turning Insights into Action to Reduce Drug Prices.
